Disease relevance of Diproderm

• After 3 weeks of once-daily therapy, psoriasis subjects treated with betamethasone dipropionate (BD) ointment or diflorasone diacetate (DD) ointment showed statistically significant (p less than 0.01) improvement compared to subjects using vehicle alone [1].
• The aim of this study was to compare oral cyclosporine at 3 mg/kg/day with topical 0.05% beta-methasone-17,21-dipropionate (BDP) cream in the treatment of chronic hand eczema [2].
• Betamethasone-17-valerate (0.1%), betamethasone-17,21-dipropionate (0.05%) and budesonide (0.025%) ointments were studied in erythroderma; betamethasone-17,21-dipropionate and budesonide in psoriasis [3].
• Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream [4].
• No serious adverse events occurred, and those minor events observed were comparable between the two groups.Our conclusion is that the group III steroid solution, BD, cured the external otitis more effectively than did the HCPB solution, whether infected by bacteria or by fungi [5].

High impact information on Diproderm

• It is concluded that the generic Topilene cream is not interchangeable with the innovator Diprolene cream, and that both pharmacists and physicians should be very careful when substituting one topical steroid formulation for another [6].
• A study was done of extended maintenance therapy using either betamethasone dipropionate (Diprolene) in optimized vehicle (OV) (ointment) or placebo in patients with psoriasis vulgaris [7].
• The depressive activity on the HPA-axis in increasing order was budesonide, betamethasone-17-valerate and betamethasone-17,21-dipropionate [3].
• OBJECTIVE: His study was designed to determine whether the bioavailability of the corticosteroid component of Daivobet was equivalent to that in a corticosteroid-only formulation (Diprosone, Schering-Plough Laboratories, France) [8].
• Both corticosteroids were found to delay the appearance of the cohort of recruited cells in the S-phase, the more potent antipsoriatic (diprosone) giving the greatest delay [9].

Chemical compound and disease context of Diproderm

• No adverse experiences were seen in the Diprolene group, but one patient with psoriasis in the Dermovate group had an exacerbation of the disease and the treatment was discontinued [10].
• The efficacy and safety of betamethasone dipropionate, 0.05% in a propylene glycol base (Diprolene), was investigated in an open, fixed-dose study of thirty-one patients with resistant psoriasis [11].
• The present study was undertaken to compare the clinical benefits of prescribing ear drops containing 0.05% solution of betamethasone dipropionate (BD), and ear drops containing hydrocortisone with oxytetracycline hydrochloride and polymyxin B (HCPB), for topical treatment of external otitis [5].

Associations of Diproderm with other chemical compounds

• The human vasoconstrictor bioassay was used to assess the potency of open applications of Synemol cream (0.025%), Diprosone cream (0.05%), Aristocort-A cream (0.5%), and Valisone cream (0.1%) [12].

Analytical, diagnostic and therapeutic context of Diproderm

• A double-blind study, carried out at two centres, comparing once and twice a day application of betamethasone-17,21-dipropionate cream 0.05% (Diproderm), has shown that the efficacy in treating eczema is the same after 1 week [13].

References